Last updated on July 2018

Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)


Brief description of study

The primary objectives of this study are to evaluate the effect of Elafibranor treatment compared to placebo on 1) histological improvement and 2) all-cause mortality and liver-related outcomes in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.

Clinical Study Identifier: NCT02704403

Contact Investigators or Research Sites near you

Start Over

Alice Roudot, PharmD

H pital Beaujon
Clichy, France
0.07miles
  Connect »

Alice Roudot, PharmD

H pital Cochin
Paris, France
5.14miles
  Connect »

Alice Roudot, PharmD

Hopital Pitie-Salpetriere
Paris, France
5.67miles
  Connect »

Alice Roudot, PharmD

H pital Saint-Antoine
Paris, France
7.59miles
  Connect »

Alice Roudot, PharmD

H pital Antoine-B cl re
Clamart, France
8.06miles
  Connect »

Alice Roudot, PharmD

H pital Paul Brousse
Villejuif, France
8.21miles
  Connect »